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A B S T R A C T
Although the classical risk factors are found in the majority of patients with acute 
coronary syndromes, in a good percentage, particularly young patients, known modi-
fiable risk factors are not present. In this subgroup of patients with acute coronary 
events, thrombophilia or hypercoagulable states have been suspected and several ge-
netic variants (polymorphisms) have been found in genes related to coagulation pro-
teins, fibrinolytic system, platelet receptors, homocysteine metabolism, platelet recep-
tors, endothelial dysfunction, and abnormal blood flow. Angioproliferative disorders 
have also been reported as associated with non-atherosclerotic coronary disease. In 
this brief overview, such nonclassical risk factors and causes of coronary events are 
discussed.
I N T R O D U C T I O N
Currently the established risk factors for cardiovascular disease are largely related 
to atherosclerosis or better termed atherothrombosis. Coronary atrery thrombosis is 
the critical event precipitated by a ruptured atherosclerotic plaque leading to acute 
coronary syndromes (myocardial infarction and unstable angina). The existence of a 
prolonged hypercoagulable state preceding the thrombotic event has been postulated 
for some time and a significant association has been established between the plasma 
concentrations of a number of hemostatic variables and the frequency of myocardial 
infarction.1-14 High plasma fibrinogen, factor VII/VIIa, tissue–type plasminogen ac-
tivator and plasminogen activator inhibitor levels have been associated with at least 
as great a risk of developing myocardial infarction as cholesterol levels, especially in 
the young.
In recent years more sensitive tests have been developed which could allow for a 
more precise biochemical definition of hypercoagulable states.3,6,8,10,13,14 Mutations in 
specific coagulation genes may also provide a genetic basis for cardiovascular disease 
risk.9 The impact of certain genotypes must be examined in relation to other established 
risk factors and potentially new therapeutic strategies.
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G e N e T I C  R I S K  F A C T O R S  I N  A C U T e 
C O R O N A R y  D I S e A S e
Among others, mutations or polymorphisms of HPA-1, 
factor V Leiden, prothrombin gene variant and the methylene 
tetrahydrofolate reductase gene (MTHFR) are now listed as 
novel risk factors for acute coronary artery disease.4,8,9 Until 
recently laboratory diagnosis of thrombophilia was based on 
investigation of the plasma anticoagulant pathways to detect 
antithrombin, protein C, and protein S deficiencies and 
on the search of dysfibrinogenemia and anti-phospholipid 
anibodies/lupus anticoagulants. More recently, laboratory 
investigations have been expanded to include activated protein 
C (APC) resistance, attributable or not to the presence of the 
factor V Leiden mutation, hyperthrombinemia attributable 
to the presence of the prothrombin gene mutation G20210A 
and hyperhomocysteinemia attributable to impairment of 
the relevant metabolic pathway because of enzymatic and/or 
vitamin deficiencies.1-3,6,8-10,13,14 Education and patients’ com-
pliance are essential to successful long-term management of 
these conditions.
M y O C A R D I A l  I N F A R C T I O N  I N 
P A T I e N T S  w I T h  N O R M A l  C O R O N A R y 
A R T e R I e S
Up to 50% of patients with coronary artery disease may 
not have any of the conventional risk factors. Generally there 
is an inflammatory and a vasomotor component in the patho-
physiology of the acute coronary event in patients with normal 
coronary arteries. Prinzmetal’s variant angina, syndrome X, 
coronary embolization and congenital coronary anomalies are 
a few examples of conditions that may not be associated with 
coronary atherosclerosis and established risk factors. Novel 
risk factors that are emerging in an attempt to establish an 
etiology in this group of patients are plasma homocysteine, 
plasma fibrinogen, estrogen-deficiency, lipoprotein(a), C-
reactive protein, chlamydia pneumoniae, helicobacter pylori, 
factor VII, endogenous tissue plasminogen and endogenous 
plasminogen activator/inhibitor type I.1,2,5-10,13,14
An elevated level of total homocysteine in blood is emerg-
ing as a prevalent and strong risk factor for atherosclerotic 
vascular disease in the coronary, cerebral, and peripheral 
vessels and for arterial and venous thromboembolism.1,2 Hy-
perhomocysteinemia arising from impaired methionine 
metabolism probably usually due to a deficiency of cystath-
ionine beta-synthase is associated with premature cerebral, 
peripheral and possibly coronary vascular disease. However, 
it is not entirely clear whether hyperhomocysteinemia is a 
risk factor or a consequence of ischemic heart disease, and 
its role in patients with premature coronary artery disease is 
not certain. Although there is a considerable epidemiologic 
evidence for a relationship between plasma homocysteine 
levels and cardiovascular disease, not all studies have shown 
such a relationship. Nevertheless, latest studies show that hy-
perhomocysteinemia represents an independent risk factor for 
acute coronary thrombosis rather than for the development of 
coronary atherosclerosis. Therefore, hyperhomocysteinemia 
may influence the clinical situation after plaque rupture not 
only by prothrombotic action but also by favoring endothelial 
dysfunction and vasospasm.
A N G I O P R O l I F e R A T I v e  D I S O R D e R S 
A N D  I S C h e M I C  h e A R T  D I S e A S e
Kimura’s disease is an allergic, inflammatory disorder of 
unknown cause. It mainly affects men who present with lym-
phadenopathy, peripheral eosinophilia and elevated serum 
IgE.11,12 Angiolymphoid hyperplasia with eosinophilia (ALHE) 
is another angioproliferative disorder. Endothelial prolifera-
tion is more pronounced in Kimura’s disease and is lacking the 
atypical histocytoid endothelial cells characteristic of ALHE. 
Compared with Kimura’s disease, ALHE is more variable in its 
clinical, histopathologic and immunohistochemical features. 
Subcutaneous mass lesions of the head and neck are common 
in angiolymphoid hyperplasia with eosinophilia as well as in 
Kimura’s disease, most often in the periauricular location 
in young and middle-aged adults. In ALHE the lesions are 
smaller and more superficial. The diagnosis is confirmed by 
biopsy. Various treatment modalities have been suggested for 
the management of these conditions. Oral corticosteroids have 
been the mainstay of therapy.
In the literature there are a few cases of young patients 
with hypereosinophilia associated with Kimura’s disease who 
showed repeated life-threatening syncopal attacks during 
daily activities or at rest or presented with acute myocardial 
infarction. Coronary angiograms demonstrated small aneu-
rysms with irregular vessel walls of coronary arteries and the 
absence of organic stenotic lesions. These case reports suggest 
the need to extend the concept of conventional risk factors 
for coronary artery disease in young patients with myocardial 
infarction and normal coronary arteries.
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